Titlebook: Clinical Applications of Immunotoxins; Arthur E. Frankel (Associate Professor of Medicine Book 1998 The Editor(s) (if applicable) and The

vitamin-D

書目名稱Clinical Applications of Immunotoxins影響因子(影響力)




書目名稱Clinical Applications of Immunotoxins影響因子(影響力)學(xué)科排名




書目名稱Clinical Applications of Immunotoxins網(wǎng)絡(luò)公開度




書目名稱Clinical Applications of Immunotoxins網(wǎng)絡(luò)公開度學(xué)科排名




書目名稱Clinical Applications of Immunotoxins被引頻次




書目名稱Clinical Applications of Immunotoxins被引頻次學(xué)科排名




書目名稱Clinical Applications of Immunotoxins年度引用




書目名稱Clinical Applications of Immunotoxins年度引用學(xué)科排名




書目名稱Clinical Applications of Immunotoxins讀者反饋




書目名稱Clinical Applications of Immunotoxins讀者反饋學(xué)科排名

法律的瑕疵

The Emerging Role of Ricin A-Chain Immunotoxins in Leukemia and Lymphoma,timately die of their disease. The major reason for this poor outcome is the persistence or selection of cells which are refractory to conventional treatment. These cells might be eradicated by new immunotherapeutic agents with different modes of action. In this regard, monoclonal antibodies (Moabs)

脫離

Clinical Trials with Blocked Ricin Immunotoxins,unately, even with the development of innovative multi-drug treatment regimens and the increasing availability of both autologous bone marrow transplantation (ABMT) and peripheral blood stem cell transplantation (PBSCT), the clinician lacks the necessary tools to successfully combat the progression

油氈

invade

Diphtheria Toxin Fusion Proteins,ting of monoclonal antibodies chemically linked through a disulfide bond to a plant or bacterial toxin or radionuclide. Instability of the chemical conjugation of some of the earlier immunotoxins led to the concept of using protein engineering and recombinant DNA to assemble fusion genes combining t

Trigger-Point

Trigger-Point

北極人

絕食

NOTCH

T. E. Cooke,J. Matatko,D. C. Staffordon of so many colleagues in this field in this book has been a reflection both of the kindness and friendliness of the individuals as well as their commitment to working together to develop a new class of human therapeutics.